245 related articles for article (PubMed ID: 32564395)
21. Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma.
Nosaka K; Crawford B; Yi J; Kuan W; Matsumoto T; Takahashi T
Eur J Haematol; 2022 Mar; 108(3):212-222. PubMed ID: 34862665
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
Ishitsuka K; Yurimoto S; Kawamura K; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
Int J Hematol; 2017 Oct; 106(4):522-532. PubMed ID: 28597329
[TBL] [Abstract][Full Text] [Related]
23. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
Tobinai K; Takahashi T; Akinaga S
Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
[TBL] [Abstract][Full Text] [Related]
24. Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma.
Shimazu Y; Nohgawa M
Leuk Lymphoma; 2019 Dec; 60(12):3092-3093. PubMed ID: 31104532
[No Abstract] [Full Text] [Related]
25. Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma.
Jo T; Matsuzaka K; Shioya H; Tominaga H; Sakai T; Kaneko Y; Hayashi S; Matsuo M; Taguchi J; Abe K; Shigematsu K; Kubota-Koketsu R
Anticancer Res; 2020 Sep; 40(9):5237-5243. PubMed ID: 32878812
[TBL] [Abstract][Full Text] [Related]
26. Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases.
Morichika K; Tomoyose T; Hanashiro T; Shimabukuro N; Tamaki K; Tedokon I; Nishi Y; Nakachi S; Karube KN; Fukushima T; Katoh T; Ohshima K; Masuzaki H
Intern Med; 2016; 55(10):1345-9. PubMed ID: 27181545
[TBL] [Abstract][Full Text] [Related]
27. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
[TBL] [Abstract][Full Text] [Related]
28. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
Kawano N; Yoshida S; Kuriyama T; Tahara Y; Yamashita K; Nagahiro Y; Kawano J; Koketsu H; Toyofuku A; Manabe T; Beppu K; Ono N; Himeji D; Yokota-Ikeda N; Inoue S; Ochiai H; Sonoda KH; Shimoda K; Ishikawa F; Ueda A
Intern Med; 2015; 54(12):1489-98. PubMed ID: 26073237
[TBL] [Abstract][Full Text] [Related]
29. Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities.
Hleihel R; Akkouche A; Skayneh H; Hermine O; Bazarbachi A; El Hajj H
Curr Oncol Rep; 2021 Nov; 23(12):141. PubMed ID: 34735653
[TBL] [Abstract][Full Text] [Related]
30. Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.
Yonekura K; Kusumoto S; Choi I; Nakano N; Ito A; Suehiro Y; Imaizumi Y; Yoshimitsu M; Nosaka K; Ohtsuka E; Hidaka M; Jo T; Sasaki H; Moriuchi Y; Ogata M; Tatetsu H; Ishitsuka K; Miyazaki Y; Ueda R; Utsunomiya A; Ishida T
Blood Adv; 2020 Oct; 4(20):5133-5145. PubMed ID: 33091125
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
Mukai M; Maeda H; Narushima K; Mould DR; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
[TBL] [Abstract][Full Text] [Related]
32. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
[TBL] [Abstract][Full Text] [Related]
33. CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
Sakamoto Y; Ishida T; Masaki A; Murase T; Ohtsuka E; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
Hematol Oncol; 2022 Dec; 40(5):876-884. PubMed ID: 36043457
[TBL] [Abstract][Full Text] [Related]
34. [Adult T cell leukemia-lymphoma with allo-HSCT after treatment for pulmonary involvement with Mogamulizumab].
Kawashima I; Sueki Y; Yamamoto T; Nozaki Y; Nakajima K; Mitsumori T; Kirito K
Rinsho Ketsueki; 2015 Feb; 56(2):210-5. PubMed ID: 25765802
[TBL] [Abstract][Full Text] [Related]
35. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
[TBL] [Abstract][Full Text] [Related]
36. A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.
Sekiguchi Y; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Kinoshita A; Suga Y; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(9):6278-90. PubMed ID: 25337281
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
Nosaka K; Kusumoto S; Nakano N; Choi I; Yoshimitsu M; Imaizumi Y; Hidaka M; Sasaki H; Makiyama J; Ohtsuka E; Jo T; Ogata M; Ito A; Yonekura K; Tatetsu H; Kato T; Kawakita T; Suehiro Y; Ishitsuka K; Iida S; Matsutani T; Utsunomiya A; Ueda R; Ishida T
Br J Haematol; 2022 Feb; 196(3):629-638. PubMed ID: 34632569
[TBL] [Abstract][Full Text] [Related]
38. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo.
Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y
Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259
[TBL] [Abstract][Full Text] [Related]
39. Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.
Sharma K; Janik JE; O'Mahony D; Stewart D; Pittaluga S; Stetler-Stevenson M; Jaffe ES; Raffeld M; Fleisher TA; Lee CC; Steinberg SM; Waldmann TA; Morris JC
Clin Cancer Res; 2017 Jan; 23(1):35-42. PubMed ID: 27486175
[TBL] [Abstract][Full Text] [Related]
40. Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia-lymphoma treated with mogamulizumab.
Tamaki K; Kinjo T; Aoyama H; Tomoyose T; Nakachi S; Hanashiro T; Shimabukuro N; Tedokon I; Morichika K; Nishi Y; Taira N; Fujita J; Yoshimi N; Fukushima T; Masuzaki H
J Infect Chemother; 2015 Nov; 21(11):820-3. PubMed ID: 26231316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
